**Table S1:** Descriptive statistics with a summary output of mixed-model on FeNO and lung function parameters recorded at baseline and during the treatment with benralizumab (n=108 unless otherwise specified). Mean (SD) and n values or n (percentage) and beta regression coefficients with 95% CI are reported for each time point.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Parameter | Baseline | Month 6 | Month 12 | Month 24 | | | Month 36 | | p-value | |
| **FeNO** | 61.95 (55.66)  0  n=55 | 28.74 (21.06)  -29.69 (-40.63 : -18.75)  n=49 | 32.22 (20.23)  -25.27 (-37.73 : -12.8  n=35 | | | 41.25 (36.92)  -20.2 (-32.82 : -7.57)  n=33 | | 42.27 (32.31)  -18.21 (-30.01 : -6.41)  n=40 | | 0.0001 |
| **FCV predicted (%)** | 93.97 (20.73)  0  n=91 | 99.92 (20.58)  6.57 (2.99 : 10.14)  n=80 | 102.26 (24.52)  9.29 (5.49 : 13.08)  n=67 | | | 100.19 (19.42)  8.84 (4.98 : 12.71)  n=64 | | 101.59 (19.38)  8.34 (4.69 : 11.98)  n=76 | | <0.0001 |
| **Post BD FEV1** (L/min.) | 2.27 (0.72)  0  61 | 2.55 (0.77)  0.21 (0.08 : 0.34)  42 | 2.80 (0.74)  0.25 (0.09 : 0.40) | | | 2.65 (0.87)  0.14 (-0.01 : 0.28)  27 | | 2.54 (0.96)  0.16 (0.02 : 0.30)  37 | 0.0397 | |
| **Post BD FEV1 predicted (%)** | 87.13 (21.72)  0  n=63 | 93.97 (23.48)  7.34 (1.51 : 13.17)  n=42 | 99.11 (17.11)  9.72 (2.87 : 16.58)  n=27 | | | 96.8 (20.46)  7.8 (1.43 : 14.17)  n=35 | | 92.97 (25.95)  6.42 (0.3 : 12.53)  n=38 | 0.1703 | |
| **Post-BD FCV predicted (%)** | 87.06 (36.79)  0  n=60 | 102.9 (23.35)  14.03 (3.28 : 24.79)  n=40 | 107.93 (21.28)  16.26 (3.83 : 28.68)  n=27 | | 104.08 (31.68)  11.29 (-0.3 : 22.88)  n=34 | | | 94.36 (40.22)  3.49 (-7.59 : 14.56)  n=38 | 0.1703 | |
| **FEV1/FVC** | 54.11 (24.87)  0  n=91 | 58.95 (25.79)  5.84 (3.52 : 8.17)  n=81 | 57.02 (27.91)  4.76 (2.28 : 7.24)  n=67 | | | 63.83 (18.93)  5.04 (2.5 : 7.58)  n=63 | | 60.7 (24.58)  6.26 (3.87 : 8.66)  n=75 | <0.0001 | |
| **Post BD FEV1/FVC** | 62.82 (21.32)  0  n=60 | 71.82 (9.8)  2.86 (0.71 : 5.01)  n=41 | 71.55 (9.69)  1.82 (-0.68 : 4.31)  n=27 | | | 69.9 (8.16)  1.12 (-1.21 : 3.44)  n=36 | | 68.66 (14.24)  2.15 (-0.06 : 4.36)  n=40 | 0.2822 | |

**Table S2:** Extent of OCS dose reduction during treatment with benralizumab in patients grouped according to OCS dose at baseline (≤5 mg/day or >5 mg/day)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Extent of OCS reduction, OCS dose at baseline ≤5 mg/day (n=26)** | **Month 6 (n=25)** | **Month 12 (n=21)** | | **Month 24 (n=21)** | **Month 36 (n=21)** |
| *Any reduction* | 20 (80%) | 20 (95.24%) | | 18 (85.71%) | 19 (90.48%) |
| *≥90 %* | 14 (56%) | 18 (85.71%) | | 16 (76.19%) | 18 (85.71%) |
| *≥75 %* | 15 (60%) | | 19 (90.48%) | 17 (80.95%) | 18 (85.71%) |
| *≥50 %* | 19 (76%) | | 20 (95.24%) | 17 (80.95%) | 19 (90.48%) |
| *≥25 %* | 20 (80%) | | 20 (95.24%) | 18 (85.71%) | 19 (90.48%) |
| *No reduction* | 5 (20%) | | 1 (4.76%) | 3 (14.29%) | 2 (9.52%) |
| *Eliminatioon* | 14 (56%) | | 18 (85.71%) | 16 (76.19%) | 18 (85.71%) |
| **Extent of OCS reduction, OCS dose at baseline >5 mg/day (n=41)** | **Month 6 (n=39)** | **Month 12 (n=26)** | | **Month 24 (n=22)** | **Month 36 (n=24)** |
| *Any reduction* | 32 (82.05%) | | 21 (80.77%) | 21 (95.45%) | 23 (95.83%) |
| *≥90 %* | 25 (64.1%) | | 16 (61.54%) | 18 (81.82%) | 20 (83.33%) |
| *≥75 %* | 27 (69.23%) | | 19 (73.08%) | 20 (90.91%) | 21 (87.5%) |
| *≥50 %* | 31 (79.49%) | | 21 (80.77%) | 21 (95.45%) | 23 (95.83%) |
| *≥25 %* | 31 (79.49%) | | 21 (80.77%) | 21 (95.45%) | 23 (95.83%) |
| *No reduction* | 7 (17.95%) | | 5 (19.23%) | 1 (4.55%) | 1 (4.17%) |
| *Elimination* | 25 (64.1%) | | 16 (61.54%) | 17 (77.27%) | 20 (83.33%) |